<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7290442\results\search\disease\results.xml">
  <result pre="; font-style : italic;} VirusesVirusesvirusesViruses1999-4915MDPI doi: 10.3390/v12050526viruses-12-00526 : Review SARS-CoV-2/COVID-19:" exact="Viral" post="Genomics, Epidemiology, Vaccines, and Therapeutic Interventions https://orcid.org/0000-0001-6867-5803UddinMohammed12â€ https://orcid.org/0000-0002-1081-3756MustafaFarah3â€ RizviTahir"/>
  <result pre="BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The COVID-19 pandemic is due to" exact="infection" post="caused by the novel SARS-CoV-2 virus that impacts the"/>
  <result pre="infection caused by the novel SARS-CoV-2 virus that impacts the" exact="lower" post="respiratory tract. The spectrum of symptoms ranges from asymptomatic"/>
  <result pre="caused by the novel SARS-CoV-2 virus that impacts the lower" exact="respiratory" post="tract. The spectrum of symptoms ranges from asymptomatic infections"/>
  <result pre="lower respiratory tract. The spectrum of symptoms ranges from asymptomatic" exact="infections" post="to mild respiratory symptoms to the lethal form of"/>
  <result pre="The spectrum of symptoms ranges from asymptomatic infections to mild" exact="respiratory" post="symptoms to the lethal form of COVID-19 which is"/>
  <result pre="lethal form of COVID-19 which is associated with severe pneumonia," exact="acute" post="respiratory distress, and fatality. To address this global crisis,"/>
  <result pre="form of COVID-19 which is associated with severe pneumonia, acute" exact="respiratory" post="distress, and fatality. To address this global crisis, up-to-date"/>
  <result pre="and fatality. To address this global crisis, up-to-date information on" exact="viral" post="genomics and transcriptomics is crucial for understanding the origins"/>
  <result pre="origins and global dispersion of the virus, providing insights into" exact="viral" post="pathogenicity, transmission, and epidemiology, and enabling strategies for therapeutic"/>
  <result pre="to therapeutics related to COVID-19 treatment. SARS-CoV-2 COVID-19 coronavirus pandemic" exact="viral" post="genomics 1. Introduction In December 2019, several cases of"/>
  <result pre="1. Introduction In December 2019, several cases of a new" exact="respiratory" post="illness were described in Wuhan, Hubei Province, China. By"/>
  <result pre="Province, China. By January 2020, it was confirmed that these" exact="infections" post="were caused by a novel coronavirus which was subsequently"/>
  <result pre="a novel coronavirus which was subsequently named SARS-CoV-2, while the" exact="disease" post="it caused COVID-19 [1,2]. This novel coronavirus is closely"/>
  <result pre="fears of a global recession. As the number of confirmed" exact="infections" post="and fatalities continue to increase daily, it is crucial"/>
  <result pre="addition to informing preventive policies and patient care decisions. The" exact="primary" post="purpose of this review is to provide an update"/>
  <result pre="transcriptomics of SARS-CoV-2, as well as therapeutic interventions in the" exact="absence of" post="a vaccine. Furthermore, we examine how the viral genomics"/>
  <result pre="the absence of a vaccine. Furthermore, we examine how the" exact="viral" post="genomics and molecular epidemiology informs therapeutic and vaccine development"/>
  <result pre="intensive critical care [5,7,8]. The severity and outcome of the" exact="disease" post="seem to be highly correlated with the age of"/>
  <result pre="â‰¥85 years [5,7,8,9]. Individuals with underlying health issues such as" exact="cardiovascular" post="disorders, diabetes, liver, and kidney disease, malignant tumors, or"/>
  <result pre="underlying health issues such as cardiovascular disorders, diabetes, liver, and" exact="kidney disease," post="malignant tumors, or a suppressed immune system, seem to"/>
  <result pre="issues such as cardiovascular disorders, diabetes, liver, and kidney disease," exact="malignant" post="tumors, or a suppressed immune system, seem to have"/>
  <result pre="immune system, seem to have the severe form of the" exact="disease" post="and increased fatality rate [5,7,8,9,10]. Current evidence suggests that"/>
  <result pre="a series of well-controlled experiments revealed that the virus remained" exact="infectious" post="in aerosols throughout the duration of the experiment (3"/>
  <result pre="in relation to surfaces, SARS-CoV-2 was found to be most" exact="stable" post="on plastic and stainless steel with infectious virus detected"/>
  <result pre="to be most stable on plastic and stainless steel with" exact="infectious" post="virus detected up to 72 h post-application and no"/>
  <result pre="infectious virus detected up to 72 h post-application and no" exact="infectious" post="virus was found on copper or cardboard after 4"/>
  <result pre="are more likely due to other factors such as high" exact="viral" post="loads in the upper respiratory tract and the potential"/>
  <result pre="to other factors such as high viral loads in the" exact="upper" post="respiratory tract and the potential for individuals infected with"/>
  <result pre="other factors such as high viral loads in the upper" exact="respiratory" post="tract and the potential for individuals infected with SARS-CoV-2"/>
  <result pre="1) of SARS-CoV-2 is highly plausible as the virus remains" exact="infectious" post="in droplets for numerous hours and on surfaces for"/>
  <result pre="though epidemiological evidence minimizes the relevance of such transmission to" exact="disease" post="spread [23,24]. Box 1 SARS CoV-2-related Definitions. SARS-CoV-2: Severe"/>
  <result pre="to disease spread [23,24]. Box 1 SARS CoV-2-related Definitions. SARS-CoV-2:" exact="Severe" post="acute respiratory syndrome coronavirus 2 COVID-19 or Covid-19: Corona"/>
  <result pre="disease spread [23,24]. Box 1 SARS CoV-2-related Definitions. SARS-CoV-2: Severe" exact="acute" post="respiratory syndrome coronavirus 2 COVID-19 or Covid-19: Corona virus"/>
  <result pre="spread [23,24]. Box 1 SARS CoV-2-related Definitions. SARS-CoV-2: Severe acute" exact="respiratory" post="syndrome coronavirus 2 COVID-19 or Covid-19: Corona virus disease,"/>
  <result pre="[23,24]. Box 1 SARS CoV-2-related Definitions. SARS-CoV-2: Severe acute respiratory" exact="syndrome" post="coronavirus 2 COVID-19 or Covid-19: Corona virus disease, 2019."/>
  <result pre="virus disease, 2019. COVID-19 is the official name of the" exact="disease" post="manifested by SARS-CoV-2. R0: Reproduction number that defines the"/>
  <result pre="by SARS-CoV-2. R0: Reproduction number that defines the number of" exact="secondary" post="cases that will be produced by a single infectious"/>
  <result pre="of secondary cases that will be produced by a single" exact="infectious" post="index case in a population that is fully susceptible"/>
  <result pre="example, a R0 of 2 means that, on average, one" exact="primary" post="index case would infect two other people, generating two"/>
  <result pre="primary index case would infect two other people, generating two" exact="secondary" post="cases. Continuous horizontal (human-to-human) transmission will occur if R0"/>
  <result pre="would infect two other people, generating two secondary cases. Continuous" exact="horizontal" post="(human-to-human) transmission will occur if R0 is above the"/>
  <result pre="inanimate object (i.e., surface) when contaminated with or exposed to" exact="infectious" post="agent, can serve as a source to transmit the"/>
  <result pre="(i.e., physical [â€œsocialâ€�] distancing) can be very effective to contain" exact="viral" post="shedding. 3. Genomics of SARS-CoV-2 SARS-CoV-2 is a Î²-coronavirus"/>
  <result pre="a Î²-coronavirus similar to the viruses that cause SARS (severe" exact="acute" post="respiratory syndrome) and MERS (Middle East respiratory syndrome). Human"/>
  <result pre="Î²-coronavirus similar to the viruses that cause SARS (severe acute" exact="respiratory" post="syndrome) and MERS (Middle East respiratory syndrome). Human coronaviruses"/>
  <result pre="cause SARS (severe acute respiratory syndrome) and MERS (Middle East" exact="respiratory" post="syndrome). Human coronaviruses are not new and have been"/>
  <result pre="[25]. Of the seven virus species known, four infect the" exact="upper" post="respiratory tract and cause mild symptoms, while three are"/>
  <result pre="Of the seven virus species known, four infect the upper" exact="respiratory" post="tract and cause mild symptoms, while three are associated"/>
  <result pre="and cause mild symptoms, while three are associated with the" exact="lower" post="respiratory tract, causing severe disease, including SARS-CoV, MERS-CoV, and"/>
  <result pre="cause mild symptoms, while three are associated with the lower" exact="respiratory" post="tract, causing severe disease, including SARS-CoV, MERS-CoV, and now"/>
  <result pre="non-segmented genome ~30 kb in size [11,27] (Figure 1). The" exact="viral" post="genome codes for 16 non-structural proteins (Nsps) required for"/>
  <result pre="Phylogenetic analyses of SARS-CoV-2 genomes have identified bats as the" exact="primary" post="reservoir of SARS-like coronaviruses [30] displaying high sequence similarity"/>
  <result pre="between BatCoV and SARS-CoV-2 genomes [31]. Sequence analysis of the" exact="viral" post="spike protein further suggests new mutations in its RBD"/>
  <result pre="made in viruses from pangolin SARSr-CoVs, one of the putative" exact="intermediate" post="host species that may have been used by SARS-CoV-2"/>
  <result pre="analysis does not prove the potential of Pangolin as the" exact="intermediate" post="host of SARS-CoV-2. Sequences of SARS-CoV-2 have now been"/>
  <result pre="[11,35]. More importantly, in case of an inability to diagnose" exact="infections" post="empirically due to the speed of epidemics or lack"/>
  <result pre="transcriptomic insights should further provide a better understanding of the" exact="viral" post="life cycle and its virulence. After cell entry, the"/>
  <result pre="recent independent studies [28,46]. ACE2 is primarily found in the" exact="lower" post="respiratory tract of humans on epithelial cells lining the"/>
  <result pre="independent studies [28,46]. ACE2 is primarily found in the lower" exact="respiratory" post="tract of humans on epithelial cells lining the lung"/>
  <result pre="primarily found in the lower respiratory tract of humans on" exact="epithelial" post="cells lining the lung alveoli and bronchioles as well"/>
  <result pre="bronchioles as well as the endothelial cells and myocytes of" exact="pulmonary" post="blood vessels, partly explaining the severe respiratory syndrome associated"/>
  <result pre="as well as the endothelial cells and myocytes of pulmonary" exact="blood vessels," post="partly explaining the severe respiratory syndrome associated with these"/>
  <result pre="and myocytes of pulmonary blood vessels, partly explaining the severe" exact="respiratory" post="syndrome associated with these viruses [48]. Its expression in"/>
  <result pre="myocytes of pulmonary blood vessels, partly explaining the severe respiratory" exact="syndrome" post="associated with these viruses [48]. Its expression in the"/>
  <result pre="associated with these viruses [48]. Its expression in the nasal" exact="epithelial" post="cells of the upper respiratory tract has recently been"/>
  <result pre="[48]. Its expression in the nasal epithelial cells of the" exact="upper" post="respiratory tract has recently been confirmed using single cell"/>
  <result pre="Its expression in the nasal epithelial cells of the upper" exact="respiratory" post="tract has recently been confirmed using single cell RNAseq"/>
  <result pre="which may further explain the gastrointestinal symptoms associated with the" exact="viral infection" post="as well as its detection in faeces [50]. In"/>
  <result pre="may further explain the gastrointestinal symptoms associated with the viral" exact="infection" post="as well as its detection in faeces [50]. In"/>
  <result pre="also shown to be different between males and females. The" exact="viral" post="spike (S) protein is responsible for viral entry into"/>
  <result pre="and females. The viral spike (S) protein is responsible for" exact="viral" post="entry into susceptible cells by interacting with the ACE2"/>
  <result pre="interact with the ACE2 receptor, while the S2 subunit facilitates" exact="viral" post="fusion with the host cell membrane, allowing virus entry"/>
  <result pre="cell [46] (Figure 1a). The current knowledge of the cellular" exact="infection" post="pathway involving ACE2 and TMPRSS2 thus provide good candidates"/>
  <result pre="gold standard for diagnosing COVID-19 depends upon detection of the" exact="viral" post="genetic material (RNA) in a nasopharyngeal swab or sputum"/>
  <result pre="is essential to apply next generation sequencing to identify the" exact="viral" post="genome with specific mutations. Currently, â€œsequencing by synthesisâ€� technique"/>
  <result pre="Oxford Nanopore Technology, Oxford, UK) are being used to identify" exact="viral" post="genomes at single-base resolution levels [11,27,35]. Although nanopore sequencing"/>
  <result pre="antibody associated tests are faster, their use for diagnosis is" exact="limited" post="by the fact that it usually takes several days"/>
  <result pre="takes several days and up to two weeks after an" exact="infection" post="takes place for antibodies to be detectable. Therefore, antibody-based"/>
  <result pre="susceptible individuals. A third type of testing relies on detecting" exact="viral" post="proteins (antigens) likely to be useful since they do"/>
  <result pre="vaccines, mostly on the spike protein and 5 on VLPs)," exact="viral" post="vector-based vaccines (~25 teams with one in clinical trial),"/>
  <result pre="it for future protection. Furthermore, such a vaccine can prevent" exact="infection" post="since it would inhibit virus entry into susceptible cells."/>
  <result pre="lightning speed (within 45 days of publication of the first" exact="viral" post="genome) by Moderna Therapeutics (Cambridge, MA, USA) who was"/>
  <result pre="developing other novel vaccine approaches and therapeutic interventions to combat" exact="viral infection" post="[57,59,60]. For example, Inovio Pharmaceuticalsâ€™ INO-4800 (Plymouth Meeting, PA,"/>
  <result pre="other novel vaccine approaches and therapeutic interventions to combat viral" exact="infection" post="[57,59,60]. For example, Inovio Pharmaceuticalsâ€™ INO-4800 (Plymouth Meeting, PA,"/>
  <result pre="a reverse strategy to create a live-attenuated vaccine in which" exact="viral" post="sequences have been changed by swapping its optimized codons"/>
  <result pre="a classic adaptive immunotherapy that has been applied to many" exact="infectious diseases" post="for more than a century for prevention and treatment."/>
  <result pre="over the last two decades against SARS, MERS, and H1N1" exact="infection" post="[61,62,63]. In this therapy, plasma (with neutralizing antibodies) is"/>
  <result pre="Enzyme 2 (ACE2) ACE2 is the host receptor for SARS-CoV-2" exact="infection" post="that interacts with the viral spike protein to gain"/>
  <result pre="the host receptor for SARS-CoV-2 infection that interacts with the" exact="viral" post="spike protein to gain entry into human cells; therefore,"/>
  <result pre="soluble ACE2, could curtail replication of SARS-CoV-2, resulting in reduced" exact="viral" post="loads drastically in Vero cells in a dose dependent"/>
  <result pre="Furthermore, they go on to show that hrsACE2 could inhibit" exact="virus infection" post="of human engineered blood vessel and kidney organoids. These"/>
  <result pre="they go on to show that hrsACE2 could inhibit virus" exact="infection" post="of human engineered blood vessel and kidney organoids. These"/>
  <result pre="new window of opportunity to use hrsACE2 to prevent SARS-CoV-2" exact="infection" post="at a very early stage by blocking its entry"/>
  <result pre="for COVID-19 Given the need to find effective treatment for" exact="symptomatic" post="patients, the approach of repurposing old drugs with antiviral"/>
  <result pre="antiviral properties and agents approved or under investigation for other" exact="viral" post="infections has been adopted. In the abscence of a"/>
  <result pre="properties and agents approved or under investigation for other viral" exact="infections" post="has been adopted. In the abscence of a vaccine,"/>
  <result pre="Japan that is safe and has been effective in other" exact="viral" post="infections, including influenza [76,77]. It has now been shown"/>
  <result pre="demonstrated much better therapeutic response especially with regard to faster" exact="viral" post="clearance and improvement rate in chest imaging. Based on"/>
  <result pre="with regard to faster viral clearance and improvement rate in" exact="chest" post="imaging. Based on these encouraging results, favipiravir has been"/>
  <result pre="Chloroquine/Hydroxychloroquine: Chloroquine is an inexpensive drug for the treatment of" exact="malaria" post="and features on the WHO list of essential medicines."/>
  <result pre="also used as an anti-inflammatory agent for the treatment of" exact="autoimmune diseases." post="Chloroquine is thought to inhibit virus replication by increasing"/>
  <result pre="in China has reported efficacy with amelioration of exacerbation of" exact="pneumonia" post="and acceptable safety margin with use of chloroquine for"/>
  <result pre="[10]. Hydroxychloroquine is an analogue of chloroquine which is more" exact="stable" post="with better clinical safety profile and has anti-SARS-CoV-2 activity."/>
  <result pre="polymerase enzyme of coronaviruses [86,87]. Thus, one reason for the" exact="limited" post="success of some of these clinical trials could be"/>
  <result pre="of some of these clinical trials could be due to" exact="absence of" post="zinc supplementation which may be necessary to observe the"/>
  <result pre="effects of these drugs on SARS-CoV-2 and other RNA virus" exact="infections" post="[88]. Remdesivir (GS-5734): Remdesivir is a nucleotide analogue prodrug"/>
  <result pre="it blocks RNA-dependent RNA polymerase, an enzyme that replicates the" exact="viral" post="genome, inhibiting an early step in virus replication, compared"/>
  <result pre="other RNA viruses, but has not been approved for any" exact="disease" post="[83,89,92,93]. In a compassionate use of remdesivir in a"/>
  <result pre="a small hand-held nebulizer. It was developed for the severe" exact="lung disease" post="chronic-obstructive pulmonary disorder (COPD), but, due to the current"/>
  <result pre="small hand-held nebulizer. It was developed for the severe lung" exact="disease" post="chronic-obstructive pulmonary disorder (COPD), but, due to the current"/>
  <result pre="nebulizer. It was developed for the severe lung disease chronic-obstructive" exact="pulmonary" post="disorder (COPD), but, due to the current COVID-19 crisis,"/>
  <result pre="(IL-6R) that is approved by FDA to treat patients with" exact="rheumatoid arthritis," post="systemic juvenile idiopathic arthritis, and giant cell arteritis [96]."/>
  <result pre="is approved by FDA to treat patients with rheumatoid arthritis," exact="systemic" post="juvenile idiopathic arthritis, and giant cell arteritis [96]. IL-6"/>
  <result pre="approved by FDA to treat patients with rheumatoid arthritis, systemic" exact="juvenile idiopathic arthritis," post="and giant cell arteritis [96]. IL-6 has been shown"/>
  <result pre="with this, administration of tocilizumab in a COVID-19 patient with" exact="pneumonia" post="in Italy showed favorable changes of CT findings within"/>
  <result pre="severely ill COVID-19 patients. Kinases: p21-activated protein kinases (PAKs) are" exact="cytosolic" post="serine/threonine protein kinases downstream of small (p21) GTPases, including"/>
  <result pre="(p21) GTPases, including members of the Cdc42 and Rac families." exact="Multiple" post="studies have shown that the major pathogenic kinase in"/>
  <result pre="no vaccines or specific pharmacological interventions available to contain the" exact="horizontal" post="transmission of SARS-CoV-2. Moreover, effective COVID-19-specific pharmaceutical interventions and"/>
  <result pre="early case identification and isolation, vigilant contact tracing of potential" exact="secondary" post="cases, travel restrictions and bans, stringent contact reductions, physical"/>
  <result pre="on lowering the reproductive number and slowing the rate of" exact="viral" post="transmission, if implemented early in the outbreak [109]. These"/>
  <result pre="interim measures as the quest for better understanding of the" exact="viral" post="genomics continues and the information garnered unlocks the doors"/>
  <result pre="available, it is likely that non-pharmacological interventions will remain the" exact="primary" post="line of defense to contain this pandemic. Therefore, accurate"/>
  <result pre="as it has been hypothesized that universal Bacillus Calmette-GuÃ©rin (BCG)" exact="childhood" post="vaccine may influence the transmission patterns of SARS-CoV-2 as"/>
  <result pre="related to pathogenicity, transmissibility, and response to therapy of the" exact="viral" post="isolates for local and global populations. Understanding the genetic"/>
  <result pre="local and global populations. Understanding the genetic makeup of the" exact="viral" post="strains is also critical for drug discovery and designing"/>
  <result pre="artificial intelligence (AI) should be evaluated to predict and track" exact="infections" post="before the outbreak happens. Bluedot Inc., a Canadian AI"/>
  <result pre="the outbreak happens. Bluedot Inc., a Canadian AI company for" exact="infectious diseases," post="flagged unusual infection related activity in Wuhan, China and"/>
  <result pre="Inc., a Canadian AI company for infectious diseases, flagged unusual" exact="infection" post="related activity in Wuhan, China and reported the spread"/>
  <result pre="officially declared the outbreak [112]. In this era of emerging" exact="viral" post="infections, the global community must work together and deploy"/>
  <result pre="and approved the submitted manuscript. Funding This research received no" exact="external" post="funding. Conflicts of Interest The authors declare no conflict"/>
  <result pre="https://coronavirus.jhu.edu/map.html(accessed on 9 May 2020) 5.GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.LiuL.ShanH.LeiC.L.HuiD.S.C.et al.Clinical Characteristics of Coronavirus" exact="Disease" post="2019 in ChinaN. Engl. J. Med.20203821708172010.1056/NEJMoa200203232109013 6.YangX.YuY.XuJ.ShuH.XiaJ.LiuH.WuY.ZhangL.YuZ.FangM.et al.Clinical course"/>
  <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: A single-centered, retrospective, observational studyLancet Respir."/>
  <result pre="Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus" exact="Disease" post="in South KoreaOsong Public Health Res. Perspect20201181410.24171/j.phrp.2020.11.1.0332149037 8.collab: Center"/>
  <result pre="in South KoreaOsong Public Health Res. Perspect20201181410.24171/j.phrp.2020.11.1.0332149037 8.collab: Center for" exact="Disease" post="Control, U.Severe Outcomes among Patients with Coronavirus Disease Disease"/>
  <result pre="Center for Disease Control, U.Severe Outcomes among Patients with Coronavirus" exact="Disease" post="Disease 2019 (COVID-19)â€&quot;United States, February 12-March 16, 2020Morb. Mortal."/>
  <result pre="for Disease Control, U.Severe Outcomes among Patients with Coronavirus Disease" exact="Disease" post="2019 (COVID-19)â€&quot;United States, February 12-March 16, 2020Morb. Mortal. Wkly."/>
  <result pre="February 12-March 16, 2020Morb. Mortal. Wkly. Rep. (MMWR)20206934334610.15585/mmwr.mm6912e232214079 9.LiR.PeiS.ChenB.SongY.ZhangT.YangW.ShamanJ.Substantial undocumented" exact="infection" post="facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)Science202036848949310.1126/science.abb322132179701 10.GaoJ.TianZ.YangX.Breakthrough:"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 11.AndersenK.G.RambautA.LipkinW.I.HolmesE.C.GarryR.F.The proximal origin of SARS-CoV-2Nat."/>
  <result pre="origin of SARS-CoV-2Nat. Med.20202645045210.1038/s41591-020-0820-932284615 12.SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High Contagiousness and Rapid Spread of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2Emerg. Infect. Dis.202026in press10.3201/eid2607.200282 13.ZhuY.ChenY.Q.On"/>
  <result pre="of SARS-CoV-2Nat. Med.20202645045210.1038/s41591-020-0820-932284615 12.SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High Contagiousness and Rapid Spread of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2Emerg. Infect. Dis.202026in press10.3201/eid2607.200282 13.ZhuY.ChenY.Q.On a"/>
  <result pre="SARS-CoV-2Nat. Med.20202645045210.1038/s41591-020-0820-932284615 12.SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High Contagiousness and Rapid Spread of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2Emerg. Infect. Dis.202026in press10.3201/eid2607.200282 13.ZhuY.ChenY.Q.On a Statistical"/>
  <result pre="Med.20202645045210.1038/s41591-020-0820-932284615 12.SancheS.LinY.T.XuC.Romero-SeversonE.HengartnerN.KeR.High Contagiousness and Rapid Spread of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2Emerg. Infect. Dis.202026in press10.3201/eid2607.200282 13.ZhuY.ChenY.Q.On a Statistical Transmission"/>
  <result pre="of the Early Phase of COVID-19 OutbreakStat. Biosci.2020111710.1007/s12561-020-09277-032292527 14.MoriyamaM.HugentoblerW.J.IwasakiA.Seasonality of" exact="Respiratory" post="Viral InfectionsAnnu. Rev. Virol.2020in press10.1146/annurev-virology-012420-02244532196426 15.ShiP.DongY.YanH.ZhaoC.LiX.LiuW.HeM.TangS.XiS.Impact of temperature on"/>
  <result pre="the Early Phase of COVID-19 OutbreakStat. Biosci.2020111710.1007/s12561-020-09277-032292527 14.MoriyamaM.HugentoblerW.J.IwasakiA.Seasonality of Respiratory" exact="Viral" post="InfectionsAnnu. Rev. Virol.2020in press10.1146/annurev-virology-012420-02244532196426 15.ShiP.DongY.YanH.ZhaoC.LiX.LiuW.HeM.TangS.XiS.Impact of temperature on the"/>
  <result pre="temperature on the dynamics of the COVID-19 outbreak in ChinaSci." exact="Total" post="Environ.202072813889010.1016/j.scitotenv.2020.13889032339844 16.SobralM.F.F.DuarteG.B.da Penha SobralA.I.G.MarinhoM.L.M.de Souza MeloA.Association between climate variables"/>
  <result pre="Souza MeloA.Association between climate variables and global transmission oF SARS-CoV-2Sci." exact="Total" post="Environ.202072913899710.1016/j.scitotenv.2020.13899732353724 17.van DoremalenN.BushmakerT.MorrisD.H.HolbrookM.G.GambleA.WilliamsonB.N.TaminA.HarcourtJ.L.ThornburgN.J.GerberS.I.et al.Aerosol and Surface Stability of SARS-CoV-2"/>
  <result pre="J. Med.20203821564156710.1056/NEJMc200497332182409 18.BaiY.YaoL.WeiT.TianF.JinD.Y.ChenL.WangM.Presumed Asymptomatic Carrier Transmission of COVID-19JAMA20203231406140710.1001/jama.2020.2565 19.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2" exact="Viral" post="Load in Upper Respiratory Specimens of Infected PatientsN. Engl."/>
  <result pre="Carrier Transmission of COVID-19JAMA20203231406140710.1001/jama.2020.2565 19.ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.et al.SARS-CoV-2 Viral Load in Upper" exact="Respiratory" post="Specimens of Infected PatientsN. Engl. J. Med.20203821177117910.1056/NEJMc200173732074444 20.ChinA.W.H.ChuJ.T.S.PereraM.R.HuiK.P.Y.YenH.ChanM.C.W.PeirisM.PoonL.L.M.Stability of"/>
  <result pre="Potential Drug-RepurposingNature2020in press10.1038/s41586-020-2286-9 29.ZhuN.ZhangD.WangW.LiX.YangB.SongJ.ZhaoX.HuangB.ShiW.LuR.et al.A Novel Coronavirus from Patients with" exact="Pneumonia" post="in China, 2019N. Engl. J. Med.202038272773310.1056/NEJMoa200101731978945 30.LiW.ShiZ.YuM.RenW.SmithC.EpsteinJ.H.WangH.CrameriG.HuZ.ZhangH.et al.Bats are"/>
  <result pre="Med. Virol.20209252252810.1002/jmv.2570032027036 32.BelouzardS.MilletJ.K.LicitraB.N.WhittakerG.R.Mechanisms of coronavirus cell entry mediated by the" exact="viral" post="spike proteinViruses201241011103310.3390/v406101122816037 33.BollesM.DonaldsonE.BaricR.SARS-CoV and emergent coronaviruses: Viral determinants of"/>
  <result pre="mediated by the viral spike proteinViruses201241011103310.3390/v406101122816037 33.BollesM.DonaldsonE.BaricR.SARS-CoV and emergent coronaviruses:" exact="Viral" post="determinants of interspecies transmissionCurr. Opin. Virol.2011162463410.1016/j.coviro.2011.10.01222180768 34.LiF.Structure, Function, and"/>
  <result pre="Sci. Rev.2020in press10.1093/nsr/nwaa036 36.LiuP.ChenW.ChenJ.P.Viral Metagenomics Revealed Sendai Virus and Coronavirus" exact="Infection" post="of Malayan Pangolins (Manis javanica)Viruses20191197910.3390/v11110979 37.HadfieldJ.MegillC.BellS.M.HuddlestonJ.PotterB.CallenderC.SagulenkoP.BedfordT.NeherR.A.Nextstrain: Real-time tracking of"/>
  <result pre="Fidelity Mutants: A Useful Tool for Evolutionary Biology or a" exact="Complex" post="Challenge?Viruses20181060010.3390/v10110600 40.SmithE.C.The not-so-infinite malleability of RNA viruses: Viral and"/>
  <result pre="or a Complex Challenge?Viruses20181060010.3390/v10110600 40.SmithE.C.The not-so-infinite malleability of RNA viruses:" exact="Viral" post="and cellular determinants of RNA virus mutation ratesPLoS Pathog.201713e100625410.1371/journal.ppat.100625428448634"/>
  <result pre="Pathol.200420363163710.1002/path.157015141377 49.SungnakW.HuangN.BecavinC.BergM.QueenR.LitvinukovaM.Talavera-LopezC.MaatzH.ReichartD.SampaziotisF.et al.SARS-CoV-2 entry factors are highly expressed in nasal" exact="epithelial" post="cells together with innate immune genesNat. Med.20202668168710.1038/s41591-020-0868-632327758 50.OngS.W.X.TanY.K.ChiaP.Y.LeeT.H.NgO.T.WongM.S.Y.MarimuthuK.Air, Surface"/>
  <result pre="Med.20202668168710.1038/s41591-020-0868-632327758 50.OngS.W.X.TanY.K.ChiaP.Y.LeeT.H.NgO.T.WongM.S.Y.MarimuthuK.Air, Surface Environmental, and Personal Protective Equipment Contamination by" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic"/>
  <result pre="50.OngS.W.X.TanY.K.ChiaP.Y.LeeT.H.NgO.T.WongM.S.Y.MarimuthuK.Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic PatientJAMA20203231610161210.1001/jama.2020.3227"/>
  <result pre="Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic PatientJAMA20203231610161210.1001/jama.2020.3227 51.CaoY.LiL.FengZ.WanS.HuangP.SunX.WenF.HuangX.NingG.WangW.Comparative"/>
  <result pre="Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) From a Symptomatic PatientJAMA20203231610161210.1001/jama.2020.3227 51.CaoY.LiL.FengZ.WanS.HuangP.SunX.WenF.HuangX.NingG.WangW.Comparative genetic"/>
  <result pre="Virol.20209253853910.1002/jmv.25721 53.LiZ.YiY.LuoX.XiongN.LiuY.LiS.SunR.WangY.HuB.ChenW.et al.Development and Clinical Application of A Rapid IgM-IgG" exact="Combined" post="Antibody Test for SARS-CoV-2 Infection DiagnosisJ. Med. Virol.20201710.1002/jmv.2572731502247 54.StadlbauerD.AmanatF.ChromikovaV.JiangK.StrohmeierS.ArunkumarG.A.TanJ.BhavsarD.CapuanoC.KirkpatrickE.et"/>
  <result pre="53.LiZ.YiY.LuoX.XiongN.LiuY.LiS.SunR.WangY.HuB.ChenW.et al.Development and Clinical Application of A Rapid IgM-IgG Combined" exact="Antibody" post="Test for SARS-CoV-2 Infection DiagnosisJ. Med. Virol.20201710.1002/jmv.2572731502247 54.StadlbauerD.AmanatF.ChromikovaV.JiangK.StrohmeierS.ArunkumarG.A.TanJ.BhavsarD.CapuanoC.KirkpatrickE.et al.SARS-CoV-2"/>
  <result pre="Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2" exact="Infection" post="DiagnosisJ. Med. Virol.20201710.1002/jmv.2572731502247 54.StadlbauerD.AmanatF.ChromikovaV.JiangK.StrohmeierS.ArunkumarG.A.TanJ.BhavsarD.CapuanoC.KirkpatrickE.et al.SARS-CoV-2 Seroconversion in Humans: A"/>
  <result pre="graphical guideNature202058057657710.1038/d41586-020-01221-y32346146 57.AmanatF.KrammerF.SARS-CoV-2 Vaccines: Status ReportImmunity20205258358910.1016/j.immuni.2020.03.00732259480 58.ShangW.YangY.RaoY.RaoX.The outbreak of SARS-CoV-2" exact="pneumonia" post="calls for viral vaccinesNPJ Vaccines202051310.1038/s41541-020-0170-031908850 59.HodgsonJ.The pandemic pipelineNat. Biotechnol.2020in"/>
  <result pre="Vaccines: Status ReportImmunity20205258358910.1016/j.immuni.2020.03.00732259480 58.ShangW.YangY.RaoY.RaoX.The outbreak of SARS-CoV-2 pneumonia calls for" exact="viral" post="vaccinesNPJ Vaccines202051310.1038/s41541-020-0170-031908850 59.HodgsonJ.The pandemic pipelineNat. Biotechnol.2020in press10.1038/d41587-020-00005-z 60.Thanh LeT.AndreadakisZ.KumarA.Gomez"/>
  <result pre="63.KoJ.H.SeokH.ChoS.Y.HaY.E.BaekJ.Y.KimS.H.KimY.J.ParkJ.K.ChungC.R.KangE.S.et al.Challenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirus infection: A single centre experienceAntivir. Ther.20182361762210.3851/IMP324329923831 64.DuanK.LiuB.LiC.ZhangH.YuT.QuJ.ZhouM.ChenL.MengS.HuY.et al.Effectiveness"/>
  <result pre="therapeutic targetIntensive Care Med.20204658659010.1007/s00134-020-05985-932125455 68.MonteilV.KwonH.PradoP.HagelkruysA.WimmerR.A.StahlM.LeopoldiA.GarretaE.Hurtado Del PozoC.ProsperF.et al.Inhibition of SARS-CoV-2" exact="Infections" post="in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2Cell2020in"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob. Agents Chemother.2014584875488410.1128/AAC.03011-1424841269 70.ChanJ.F.YaoY.YeungM.L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.et"/>
  <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob. Agents Chemother.2014584875488410.1128/AAC.03011-1424841269 70.ChanJ.F.YaoY.YeungM.L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.et al.Treatment"/>
  <result pre="70.ChanJ.F.YaoY.YeungM.L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.et al.Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV" exact="Infection" post="in a Nonhuman Primate Model of Common MarmosetJ. Infect."/>
  <result pre="Model of Common MarmosetJ. Infect. Dis.20152121904191310.1093/infdis/jiv39226198719 71.ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.TseM.W.QueT.L.PeirisJ.S.SungJ.et al.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort"/>
  <result pre="of Common MarmosetJ. Infect. Dis.20152121904191310.1093/infdis/jiv39226198719 71.ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.TseM.W.QueT.L.PeirisJ.S.SungJ.et al.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort studyHong"/>
  <result pre="Common MarmosetJ. Infect. Dis.20152121904191310.1093/infdis/jiv39226198719 71.ChanK.S.LaiS.T.ChuC.M.TsuiE.TamC.Y.WongM.M.TseM.W.QueT.L.PeirisJ.S.SungJ.et al.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: A multicentre retrospective matched cohort studyHong Kong"/>
  <result pre="of the Index Patient Who Caused Tertiary Transmission of COVID-19" exact="Infection" post="in Korea: The Application of Lopinavir/Ritonavir for the Treatment"/>
  <result pre="The Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected" exact="Pneumonia" post="Monitored by Quantitative RT-PCRJ. Korean Med. Sci.202035e7910.3346/jkms.2020.35.e7932056407 74.YanD.LiuX.ZhuY.HuangL.DanB.ZhangG.GaoY.Factors associated"/>
  <result pre="by Quantitative RT-PCRJ. Korean Med. Sci.202035e7910.3346/jkms.2020.35.e7932056407 74.YanD.LiuX.ZhuY.HuangL.DanB.ZhangG.GaoY.Factors associated with prolonged" exact="viral" post="shedding and impact of Lopinavir/Ritonavir treatment in patients with"/>
  <result pre="infectionMedRxiv202010.1101/2020.03.22 75.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.et al.A Trial of Lopinavir-Ritonavir in Adults Hospitalized with" exact="Severe" post="Covid-19N. Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 76.FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum"/>
  <result pre="Engl. J. Med.20203821787179910.1056/NEJMoa200128232187464 76.FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc. Jpn. Acad. Ser. B Phys. Biol. Sci.20179344946310.2183/pjab.93.02728769016"/>
  <result pre="and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus" exact="infections" post="in miceFuture Virol.201381085109410.2217/fvl.13.9824563658 78.CaiQ.YangM.LiuD.ChenJ.ShuD.XiaJ.LiaoX.GuY.CaiQ.YangY.et al.Experimental Treatment with Favipiravir for"/>
  <result pre="press10.1016/j.eng.2020.03.007 79.AkpovwaH.Chloroquine could be used for the treatment of filoviral" exact="infections" post="and other viral infections that emerge or emerged from"/>
  <result pre="be used for the treatment of filoviral infections and other" exact="viral" post="infections that emerge or emerged from viruses requiring an"/>
  <result pre="used for the treatment of filoviral infections and other viral" exact="infections" post="that emerge or emerged from viruses requiring an acidic"/>
  <result pre="Ebola virus replication in vitro but failed to protect against" exact="infection" post="and disease in the in vivo guinea pig modelJ."/>
  <result pre="replication in vitro but failed to protect against infection and" exact="disease" post="in the in vivo guinea pig modelJ. Gen. Virol.2015963484349210.1099/jgv.0.00030926459826"/>
  <result pre="Gen. Virol.2015963484349210.1099/jgv.0.00030926459826 81.LiC.ZhuX.JiX.QuanquinN.DengY.Q.TianM.AliyariR.ZuoX.YuanL.AfridiS.K.et al.Chloroquine, a FDA-approved Drug, Prevents Zika Virus" exact="Infection" post="and its Associated Congenital Microcephaly in MiceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 82.OhS.ShinJ.H.JangE.J.WonH.Y.KimH.K.JeongM.G.KimK.S.HwangE.S.Anti-inflammatory activity"/>
  <result pre="a FDA-approved Drug, Prevents Zika Virus Infection and its Associated" exact="Congenital" post="Microcephaly in MiceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 82.OhS.ShinJ.H.JangE.J.WonH.Y.KimH.K.JeongM.G.KimK.S.HwangE.S.Anti-inflammatory activity of chloroquine and amodiaquine"/>
  <result pre="FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital" exact="Microcephaly" post="in MiceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 82.OhS.ShinJ.H.JangE.J.WonH.Y.KimH.K.JeongM.G.KimK.S.HwangE.S.Anti-inflammatory activity of chloroquine and amodiaquine through"/>
  <result pre="with severe COVID-19 infectionMed. Mal. Infect.2020in press10.1016/j.medmal.2020.03.00632240719 86.KaushikN.SubramaniC.AnangS.MuthumohanR.ShalimarNayakB.Ranjith-KumarC.T.SurjitM.Zinc Salts Block" exact="Hepatitis" post="E Virus Replication by Inhibiting the Activity of Viral"/>
  <result pre="Block Hepatitis E Virus Replication by Inhibiting the Activity of" exact="Viral" post="RNA-Dependent RNA PolymeraseJ. Virol.201791e00754-1710.1128/JVI.00754-1728814517 87.LiangS.H.SouthonA.G.FraserB.H.Krause-HeuerA.M.ZhangB.ShoupT.M.LewisR.VolitakisI.HanY.GreguricI.et al.Novel Fluorinated 8-Hydroxyquinoline Based"/>
  <result pre="a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe" exact="acute" post="respiratory syndrome coronavirus 2 with high potencyJ. Biol. Chem.2020in"/>
  <result pre="direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute" exact="respiratory" post="syndrome coronavirus 2 with high potencyJ. Biol. Chem.2020in press10.1074/jbc.AC120.013056"/>
  <result pre="antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory" exact="syndrome" post="coronavirus 2 with high potencyJ. Biol. Chem.2020in press10.1074/jbc.AC120.013056 91.LoM.K.JordanR.ArveyA.SudhamsuJ.Shrivastava-RanjanP.HotardA.L.FlintM.McMullanL.K.SiegelD.ClarkeM.O.et"/>
  <result pre="MERS-CoVNat. Commun.20201122210.1038/s41467-019-13940-631924756 94.GreinJ.OhmagariN.ShinD.DiazG.AspergesE.CastagnaA.FeldtT.GreenG.GreenM.L.LescureF.X.et al.Compassionate Use of Remdesivir for Patients with" exact="Severe" post="Covid-19N. Engl. J. Med.2020in press10.1056/NEJMoa200701632275812 95.WangY.ZhangD.DuG.DuR.ZhaoJ.JinY.FuS.GaoL.ChengZ.LuQ.et al.Remdesivir in adults"/>
  <result pre="arsenal against COVID-19Travel Med. Infect. Dis.2020in press10.1016/j.tmaid.2020.10167832325121 98.ZhangC.WuZ.LiJ.W.ZhaoH.WangG.Q.The cytokine release" exact="syndrome" post="(CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist"/>
  <result pre="100.CellinaM.OrsiM.BombaciF.SalaM.MarinoP.OlivaG.Favorable changes of CT findings in a patient with COVID-19" exact="pneumonia" post="after treatment with tocilizumabDiagn. Interv. Imag.2020in press10.1016/j.diii.2020.03.010 101.PascuaP.N.LeeJ.H.SongM.S.ParkS.J.BaekY.H.AnnB.H.ShinE.Y.KimE.G.ChoiY.K.Role of"/>
  <result pre="102.Van den BroekeC.RaduM.ChernoffJ.FavoreelH.W.An emerging role for p21-activated kinases (Paks) in" exact="viral" post="infectionsTrends Cell Biol.20102016016910.1016/j.tcb.2009.12.00520071173 103.BurkardC.VerheijeM.H.WichtO.van KasterenS.I.van KuppeveldF.J.HaagmansB.L.PelkmansL.RottierP.J.BoschB.J.de HaanC.A.Coronavirus cell entry"/>
  <result pre="Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human" exact="Colon Adenocarcinoma" post="and Ovarian Cancer XenograftsJ. Med. Chem.2015589334934410.1021/acs.jmedchem.5b0132926596892 108.NguyenB.C.Q.YoshimuraK.KumazawaS.TawataS.MarutaH.Frondoside A from"/>
  <result pre="of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon" exact="Adenocarcinoma" post="and Ovarian Cancer XenograftsJ. Med. Chem.2015589334934410.1021/acs.jmedchem.5b0132926596892 108.NguyenB.C.Q.YoshimuraK.KumazawaS.TawataS.MarutaH.Frondoside A from"/>
  <result pre="Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian" exact="Cancer" post="XenograftsJ. Med. Chem.2015589334934410.1021/acs.jmedchem.5b0132926596892 108.NguyenB.C.Q.YoshimuraK.KumazawaS.TawataS.MarutaH.Frondoside A from sea cucumber and"/>
  <result pre="and its interaction with its host cellular receptor, ACE2. The" exact="infection" post="pathway is shown where after docking of the virus"/>
  <result pre="particle on cell surface, the TMPRRSS2 cellular protease activates the" exact="viral" post="protein S allowing entry of SARS-CoV-2 into human cells."/>
  <result pre="of SARS-CoV-2 into human cells. The protein coded by the" exact="viral" post="genes and some of the notable interactions (dashed line)"/>
  <result pre="Data Open Science Framework: accession number doi:10.17605/OSF.IO/8F6N9 SARS-CoV-2 and Human" exact="Protein" post="Interactions Mass Spectrometry Raw Data http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD018117 SARS-CoV-2 Strains Genomic"/>
 </snippets>
</snippetsTree>
